Clinical trial
Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive…
NCT00140725 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00140725 |
|---|---|
| Title | Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV) |
| Official title | A Randomised Trial of Lamivudine Plus Interferon Versus Lamivudine for the Treatment of HBeAg Positive Chronic Hepatitis B Virus (HBV) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis B |
| Intervention type | Drug |
| Interventions | Lamivudine plus Polyethylene glyco-interferon alfa-2b, Lamivudine |
| Enrollment | 160 |
| Start date | Apr 1, 2000 |
| First posted | Sep 1, 2005 |
| Last update posted | Oct 16, 2008 |
| Countries | Hong Kong |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: